

### Committee for Risk Assessment RAC

Annex 2

**Response to comments document (RCOM)** to the Opinion proposing harmonised classification and labelling at EU level of

### perboric acid (H3BO2(O<sub>2</sub>)), monosodium salt trihydrate [1]; perboric acid, sodium salt, tetrahydrate [2]; perboric acid (HBO(O<sub>2</sub>)), sodium salt, tetrahydrate; sodium peroxoborate, hexahydrate [3]

### EC Number: 239-172-9 [1]; 234-390-0 [2] CAS Number: 13517-20-9 [1]; 37244-98-7 [2]; 10486-00-7 [3]

CLH-O-0000007161-83-01/F

### Adopted 15 September 2022

P.O. Box 400, FI-00121 Helsinki, Finland | Tel. +358 9 686180 | Fax +358 9 68618210 | echa.europa.eu

#### COMMENTS AND RESPONSE TO COMMENTS ON CLH: PROPOSAL AND JUSTIFICATION

Comments provided during consultation are made available in the table below as submitted through the web form. Any attachments received are referred to in this table and listed underneath, or have been copied directly into the table.

All comments and attachments including confidential information received during the consultation have been provided in full to the dossier submitter (Member State Competent Authority), the Committees and to the European Commission. Non-confidential attachments that have not been copied into the table directly are published after the consultation and are also published together with the opinion (after adoption) on ECHA's website. Dossier submitters who are manufacturers, importers or downstream users, will only receive the comments and non-confidential attachments, and not the confidential information received from other parties. Journal articles are not confidential; however they are not published on the website due to Intellectual Property Rights.

ECHA accepts no responsibility or liability for the content of this table.

#### Substance name: perboric acid (H3BO2(O<sub>2</sub>)), monosodium salt trihydrate [1]; perboric acid, sodium salt, tetrahydrate [2]; perboric acid (HBO(O<sub>2</sub>)), sodium salt, tetrahydrate; sodium peroxoborate, hexahydrate [3] EC number: 239-172-9 [1]; 234-390-0 [2] CAS number: 13517-20-9 [1]; 37244-98-7 [2]; 10486-00-7 [3] Dossier submitter: Sweden

#### **GENERAL COMMENTS**

Date	Country	Organisation	Type of Organisation	Comment number			
19.01.2022	Germany		MemberState	1			
Comment received							

The DE CA supports to merge Index No. 005-018-00-2 & Index No. 005-018-01-X.

According to table 5 the entry "[containing less than 0.1 % (w/w) of particles with an aerodynamic diameter of below 50  $\mu$ m]" will be removed from the identification. The specification "[containing greater or equal than 0.1 % (w/w) of particles with an aerodynamic diameter of below 50  $\mu$ m]" (Index No 005-018-01-X) seems to remain, as it is not mentioned in the section "remove". Therefore, the merged entry should comprise the aforementioned specification or it should be named in section "remove" as well.

In addition, it is proposed to consider including the category "(dusts and mists)" behind "ATE = 1.16 mg/L" in the proposed Annex VI entry.

Moreover, the report does not comprise any information on the physico-chemical properties.

#### Dossier Submitter's Response

#### **Merging entries**

Thank for supporting the merging of Index No. 005-018-00-2 & Index No. 005-018-01-X.

#### Table 5

Thank you for pointing to the editorial mistakes in Table 5. The corrections can be seen highlighted in yellow below in table 5 in Appendix 1.

### ANNEX 2 - COMMENTS AND RESPONSE TO COMMENTS ON CLH PROPOSAL ON PERBORIC ACID $(H3BO2(O_2))$ , MONOSODIUM SALT TRIHYDRATE [1]; PERBORIC ACID, SODIUM SALT, TETRAHYDRATE [2]; PERBORIC ACID $(HBO(O_2))$ , SODIUM SALT, TETRAHYDRATE; SODIUM PEROXOBORATE, HEXAHYDRATE [3]

#### **Physicochemical properties**

There is only a Reach registration available for Perboric acid, sodium salt, EC number: 234-390-0, CAS number: 11138-47-9 where there is some information on the physciochemical properties of PBS-1 and PBS-4. There is also some information from the *SCCS Opinion on sodium perborate and perboric acid* (2010) and the *European Risk Assessment Report on perboric acid, sodium salt (CAS 11138-47-9)*(2007) (both refences included in the CLH-reports) on the per(oxo)borates, including sodium peroxometaborate. The data, when found in all three information sources, appears to be consistent. Please see compiled relevant information on physicochemical properties of sodium peroxometaborate, PBS-1 and PBS-4 in the table below.

Substance name	Sodium peroxometaborate	perboric acid, sodium salt [1]; perboric acid, sodium salt, monohydrate [2]; perboric acid (HBO(O2)), sodium salt, monohydrate; sodium peroxoborate [3]; sodium perborate [4]	perboric acid (H3BO2(O2)), monosodium salt trihydrate [1]; perboric acid, sodium salt, tetrahydrate [2]; perboric acid (HBO(O2)), sodium salt, tetrahydrate; sodium peroxoborate, hexahydrate [3]
CAS number	7632-04-4	11138-47-9 [1]; 12040-72-1 [2]; 10332-33-9 [3]; 15120-21-5 [4]	13517-20-9 [1]; 37244-98-7 [2]; 10486-00-7 [3]
EC number	231-556-4	234-390-0 [1]; 234-390-0 [2]; 239-172-9 [4]	239-172-9 [1]; 234-390-0 [2]
Molecular formula	NaBO3	B2H4O8Na2	B2H408Na2.6H20
Molecular weight	81.8 g/mol	199.6 g/mol	307.6 g/mol
Boron content	13,2%	10,8%	7,0%
Physical form	Solid white amorphous powder	Solid white crystal	Solid white crystal
Melting point	63 °C	Decompose >50 - >180°C	Ca 60-65,5 °C
Boiling point	no information available	decomposition	decomposition
Water solubility	21,5 g/L	15-16 g/L	23 g/L
Dissociation constant	Not applicable due to decomposition	Not applicable due to decomposition	Not applicable due to decomposition
Partition coefficient	no information available	Not applicable (analytical difficulties)	Not applicable (analytical difficulties)

RAC thanks the Dossier Submitter for correcting the editorial mistakes and for providing the phys chem properties of the substances. The adapted Table from the Annex is included in the draft opinion.

#### **TOXICITY TO REPRODUCTION**

Date	Country	Organisation	Type of Organisation	Comment number			
20.01.2022	France		MemberState	2			
Comment re	ceived						
reproduction it has SCLs f the developr established b BauA (1998) based from i	for development or adverse effects nent of the offspr pased on the toxic . This method ha t and concluded o	al effects and fertility of s on sexual function ar ing (at 14% and 10-14 city of the boron moiet s since been reassesse on the harmonisation of	a harmonised classification effects: Repr. 1B (H360Df). nd fertility and for adverse of 4%, respectively) that were by (B) using an approach pr ed and the RAC removed th of GCL 0.3% w/w for boric a fication as Repr. 1B in 2019	Moreover, effects on oposed by e SCLs acid and six			
FR agrees with the classification proposed and comes to the same conclusion about the							

FR agrees with the classification proposed and comes to the same conclusion about the allocation of potency of PBS-4 as medium, GCL of 0.3% for development and fertility.

Page 54, table 30: we cannot find the same ED10 for the developmental effects of PBS-4 presented in the table 30. Indeed, by applying the method presented in the CLP guidance (2017) page 409, section 3.7.2.6.3.3. we obtain different results : Live foetus weight : ED10 = 271.72 mg PBS-4/kg bw/day Litter weight : ED10 = 202.68 mg PBS-4/kg bw/day

Could you please re-check your calculations? These results do not change the allocation of potency expected for PBS-4.

Dossier Submitter's Response

Thank you for your support.

We agree that there are mistakes regarding ED10 in table 30 (please see corrections in the table below). As you point out, the corrected ED10 values (calculated according to CLP guidance (2017)) do not change the potency group allocation of PBS-4.

Developmental	Dose levels (mg PBS- 4/kg bw/day)				ED (linear int of availab	erpolation	Allocation of potency group*
effects	0	100	300	1000	(mg PBS- 4/kg bw/day)	mg B/kg bw/day	
Live foetus weight (g)	3.69	3.57	3.28	2.4	<del>127.5</del> 271.7	9 19	Medium, GCL of 0.3%
Litter weight (g)	54.97	52.62	46.49	32.52	<del>197.2</del> 202.7	<del>13.8</del> 14.2	Medium, GCL of 0.3%
Post-implantation loss (%)	2.91	2.39	13.54	15.2	288.8	20.2	Medium, GCL of 0.3%
LOAEL for development	ts	300	21	Medium, GCL of 0.3%			

RAC's response

RAC thanks the Dossier Submitter for correcting the ED10s.

Date	Country	Organisation	Type of Organisation	Comment number
19.01.2022	Germany		MemberState	3
Comment re	ceived			

Fertility:

The DE CA supports the classification of sodium per(oxo)borate tetrahydrate (PBS-4) as Repr. 1B, H360F based on both a read-across to boric acid and supporting evidence from a 28-day limit test performed with PBS-4.

The DE CA agrees that the read across to boric acid is justified due to the available toxicokinetic information for per(oxo)borates and boric acid as well as the information that the main species in physiological solutions of per(oxo)borates at neutral and acidic pH is boric acid.

In 2014, the Committee for Risk Assessment (RAC) concluded in its opinion on boric acid that a classification as Repr. 1B for fertility effects, H360F is justified.

It is further agreed that the available 28-day limit test with PBS-4 alone is considered insufficient for the purpose of classification. The results from the study (decreased absolute testes weight, testicular focal tubular atrophy and inhibition of spermiation) together with read-across data on animal studies with boric acid, however, provide clear evidence of an adverse effect on fertility of PBS-4. Fertility- SCL:

RAC has concluded on harmonisation of GCL values to 0.3% w/w for boric acid. As the available data on per(oxo)borates were not considered robust enough in order to derive an ED10 by the DS, DE CA agrees that read-across data on boric acid (based on the calculated percentage of boron; ED10 of 17.5 mg B/kg bw/d) can be used for PBS-4. Thus, PBS-4 is considered to belong to the medium potency group with a GCL of 0.3% w/w and the proposed removal of the current specific concentration limit is supported.

#### Developmental effects:

Based on results of a reliable prenatal developmental toxicity study (OECD TG 414, GLP) with PBS-4 the DE CA supports to retain the existing classification Repr. 1B, H360D as there is clear evidence of structural abnormalities and malformations.

The DE CA further agrees that due to similar malformations observed after PBS-4 and boric acid exposure the data support that the read across is justified between the two substances.

Developmental effects- SCL:

It is not possible to derive an ED10 due to the low incidences of malformations observed. Therefore, DE CA supports the SCL calculation for PBS-4 based on the LOAEL for developmental effects. As the LOAEL is estimated to be 300 mg/kg bw/d PBS-4 belongs to the medium potency group, for which a GLC of 0.3% w/w applies. Thus, the proposed removal of the specific concentration limit in the current Annex VI entry is supported.

Dossier Submitter's Response

Thank you for your support.

RAC's response

RAC agrees.

#### **OTHER HAZARDS AND ENDPOINTS – Acute Toxicity**

Date	Country	Organisation	Type of Organisation	Comment number				
20.01.2022	France		MemberState	4				
Comment re	ceived							
Acute inhalation toxicity: We agree that the use of the thoracic fraction approach is not the most appropriate for classification, as the OECD technical guidelines for acute inhalation toxicity recommend using aerosols with a mass median aerodynamic diameter (MMAD) $\leq 4 \mu m$ and a geometric standard deviation (GSD) in the range of 1.0 to 3.0, so particles can reach all regions of the respiratory tract. Moreover studies show that hydrogen peroxide released by hydrolysis contributes mainly of the acute toxicity of per(oxo)borates. Therefore, the acute toxicity of per(oxo)borates would not be due to the particle diameter size.FR agrees that the cut-off value of 50 $\mu m$ for particle size should be removed. The classification Acute tox 4 H332 and the ATE of 1.16 mg/L is supported.								
Dossier Submitter's Response								
Thank you for your support.								
RAC's response								

RAC has no further comments.

Date	Country	Organisation	Type of Organisation	Comment number				
19.01.2022	Germany		MemberState	5				
Comment re	ceived	-	-	-				
Acute oral toxicity: The DS's proposal of no classification for acute oral toxicity for PBS-4 is supported.								
	Acute dermal toxicity: The DS's proposal of no classification for acute dermal toxicity for PBS-4 is supported.							
Acute inhalation toxicity: The DE CA supports the removal of the asterisk (*) indicating minimum classification and the setting of the ATE value of 1.16 mg/L based on the acute inhalation toxicity study (Study Report 1987c) considered reliable and appropriate by the DS.								
Dossier Submitter's Response								
Thank you for your support.								
RAC's response								
RAC has no further comments.								

#### ANNEX 2 - COMMENTS AND RESPONSE TO COMMENTS ON CLH PROPOSAL ON PERBORIC ACID (H3BO2(O<sub>2</sub>)), MONOSODIUM SALT TRIHYDRATE [1]; PERBORIC ACID, SODIUM SALT, TETRAHYDRATE [2]; PERBORIC ACID (HBO(O<sub>2</sub>)), SODIUM SALT, TETRAHYDRATE; SODIUM PEROXOBORATE, HEXAHYDRATE [3]

#### **APPENDIX 1**

Table 5: Proposed harmonised classification according to the CLP criteria

					Classific	ation		Labelling			
	Index No.	International Chemical Identification	EC No.	CAS No.	Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)	Specific Conc. Limits, M-factors	Notes
Current Annex VI entries	005-018-00-2	perboric acid (H3BO2(O2)), monosodium salt trihydrate; [1] perboric acid, sodium salt, tetrahydrate; [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate; [3] sodium peroxoborate hexahydrate; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	239-172-9 [1] 234-390-0 [2] 231-556-4 [3]		Repr. 1B STOT SE 3 Eye Dam. 1	H360Df H335 H318	GHS05 GHS08 GHS07 Dgr	H360Df H335 H318		Repr. 1B; H360Df: C $\geq 14 \%$ Repr. 1B; H360D: 10 % $\leq C < 14 \%$ Eye Dam. 1; H318: $C \geq 36 \%$ Eye Irrit. 2; H319: 22 % $\leq C < 36 \%$	
	005-018-01-X	perboric acid (H3BO2(O2)), monosodium salt, trihydrate; [1] perboric acid, sodium salt, tetrahydrate; [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate; [3]	239-172-9 [1] 234-390-0 [2] 231-556-4 [3]	13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3]	Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1	H360Df H332 H335 H318	GHS05 GHS08 GHS07 Dgr	H360Df H332 H335 H318		Repr. 1B; H360Df: C $\geq 14 \%$ Repr. 1B; H360D: 10 % $\leq$ C < 14 % Eye Dam. 1; H318: C $\geq$ 36 %	

ANNEX 2 - COMMENTS AND RESPONSE TO COMMENTS ON CLH PROPOSAL ON PERBORIC ACID (H3BO2(O<sub>2</sub>)), MONOSODIUM SALT TRIHYDRATE [1]; PERBORIC ACID, SODIUM SALT, TETRAHYDRATE [2]; PERBORIC ACID (HBO(O<sub>2</sub>)), SODIUM SALT, TETRAHYDRATE; SODIUM PEROXOBORATE, HEXAHYDRATE [3]

		sodium peroxoborate hexahydrate; [containing $\geq 0,1$ % (w/w) of particles with an aerodynamic diameter of below 50 µm]							Eye Irrit. 2; H319: 22 % ≤ C < 36 %	
Dossier submitter s proposal	<b>Merge:</b> 005-018-00-2 & 005-018-01-X	Retain: perboric acid (H3BO2(O2)), monosodium salt trihydrate; [1]perboric acid, sodium salt, tetrahydrate; [2]perboric acid (HBO(O2)), sodium salt, tetrahydrate; [3]sodium peroxoborate hexahydrateRemove: [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm][containing $\ge 0,1 \%$ (w/w) of particles with an aerodynamic diameter of below 50 µm]	<u>Modify:</u> 239-172-9 [1] 234-390-0 [2]	<u>Retain:</u> 13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3]	<u>Modify:</u> Repr.1B Acute Tox. 4	<u>Modify:</u> H360FD H332	<u>Retain:</u> GHS08 GHS07 Dgr	<u>Modify:</u> H360FD H332	Remove: Repr. 1B; H360Df: C $\geq$ 14 % Repr. 1B; H360D: 10 % $\leq$ C < 14 % Add: Inhalation: ATE = 1.16 mg/L (dusts and mists)	
Resulting Annex VI entry if agreed by RAC and COM	TBD	perboric acid (H3BO2(O2)), monosodium salt trihydrate; [1] perboric acid, sodium salt, tetrahydrate; [2]	239-172-9 [1] 234-390-0 [2]	13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3]	Repr. 1B Acute Tox. 4 STOT SE 3 Eye Dam. 1	H360FD H332 H335 H318	GHS05 GHS08 GHS07 Dgr	H360FD H332 H335 H318	Inhalation: ATE = 1.16 mg/L (dusts and mists) Eye Dam. 1; H318: $C \ge 36 \%$	#

#### ANNEX 2 - COMMENTS AND RESPONSE TO COMMENTS ON CLH PROPOSAL ON PERBORIC ACID (H3BO2(O<sub>2</sub>)), MONOSODIUM SALT TRIHYDRATE [1]; PERBORIC ACID, SODIUM SALT, TETRAHYDRATE [2]; PERBORIC ACID (HBO(O<sub>2</sub>)), SODIUM SALT, TETRAHYDRATE; SODIUM PEROXOBORATE, HEXAHYDRATE [3]

perboric acid			Eye Irrit. 2; H319: $22 \% \le C < 36 \%$
(HBO(O2)), sodium			
salt, tetrahydrate			ş
sodium peroxoborate			
hexahydrate [3]			